SV Health Investors β 2016 Investments
5 investments dated 2016 Β· listed companies and verified rows first Β· show all
Axon Therapies develops the SAVM procedure, an implant-free catheter-based ablation therapy that targets the right greater splanchnic nerve to reduce overactive sympathetic nerve activity in patients with heart failure with preserved ejection fraction (HFpEF).
HealthtechMedical DevicesNew York, US
Howard R. Levin(Executive Officer, Director)Mark Gelfand(Executive Officer)Mitchell S. Bloom(Executive Officer)
Board seatPaul LaVioletteΒ· per SEC Form D Β· $2M raise Β· filed Apr 2016
Marlborough, US
Bruce Robertson(Director)Lauren Jennings(Executive Officer)Christopher Kroeger(Director)Omar Amirana(Director)Warren Clark(Executive Officer)James Garvey(Director)
Board seatPaul LaVioletteΒ· per SEC Form D
HealthtechSanta Rosa, US
Yuval Binur(Director)Dan Rose(Executive Officer)Gordon Bishop(Executive Officer, Director)George Fazio(Director)David Boyle(Executive Officer)Dan T. Lemaitre(Executive Officer, Director)
Board seatPaul LaVioletteΒ· per SEC Form D
Endotronix develops the Cordella PA Sensor and Heart Failure System, an FDA-approved implantable pulmonary artery sensor and remote monitoring platform for managing NYHA class III heart failure.
Digital HealthHealthtechMedical DevicesWoodridge, US
Jonathan Jonas(Director)Harry Rowland(Executive Officer, Director)Raymond S. Barrett, Jr.(Director)Anthony I Nunez(Executive Officer, Director)Sam R. Leno(Director)Leslie A. Saxon(Director)
Board seatPaul LaVioletteΒ· per SEC Form D
HealthtechCalabasas, US
Michael Balmuth(Became Director as of July 8, 2016)Nitin Nanda, M.D.(Executive Officer, Director)John Eugene Hill(Became Director as of July 8, 2016)Deepak Chopra(Director)Vikram Marla(Resigned as director July 8, 2016)John Tadich(Became Director as of July 8, 2016)
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.